22RV1 prostate cancer cells expressing FOXA1 C-terminal truncation mutants showed an accumulation of transcriptionally active β-catenin, indicative of WNT pathway activation (Parolia et al. 2019). This evidence concerns the gene FOXA1 and prostate carcinoma.